So I think we are all familiar with the concept of the vicious cycle or the vicious vortex in bronchiectasis, that there's an initial insult to the lungs which can come from a variety of different etiologies that sets up an inflammatory process in the airways, and that inflammation leads to uh derangement in the Uh, mucosal surface of the airways and to damage and uh to the, to the small airways primarily that results in the bronchiectasis. And that damage then causes retention of, of the normal mucus that's secreted in the airways. That mucus retention affects. The ciliary function in the airways and offers the, the, uh, kind of a fertile ground for infections. And if that process goes uninterrupted, um, the patient's bronchiectasis will get worse and worse. There'll be more infections, more inflammation, more damage to the airways. So, we know we've done a reasonably good job at looking at some aspects of the vicious vortex. Um, you know, we've, we've made a lot of progress in trying to identify the trigger for the bronchiectasis, particularly, uh, triggers that might be mitigated by, by other therapeutics. Uh, we've focused a lot on airway clearance. We've, uh, you know, I think, uh, the embrace of the concept of airway clearance has helped our patients in, in terms of breaking the cycle of, uh, of the vortex. Uh, we certainly have done a lot of work in trying to deal with the infectious complications of bronchiectasis, uh, particularly Pseudomonas, uh, but also the non-tuberculous mycobacterium. But we're still left with that inflammation issue, um, which really is sort of the root of the problem in this disease, and that's why there's a lot of excitement, um, in the recent clinical trials that have, that have looked at the, uh, possibility of mitigating that inflammatory response at the level of the airways and hence, um, you know, also excitement that we now have an approved drug that actually works on that part of the cycle.
Presenter
